BioArctic Outlicenses Alpha-Synuclein Portfolio To AbbVie For Parkinson's

 
• By Sten Stovall

Move triggers $50m milestone payment to BioArctic, extending Swedish biotech's cash runway, its CEO tells Scrip.

Parkinson's disease. 3D illustration showing neurons containing Lewy bodies small red spheres which are deposits of proteins accumulated in brain cells that cause their progressive degeneration - Illustration
BAN0805 is most advanced alpha-synuclein targeting antibody in BioArctic's portfolio • Source: Shutterstock

More from Deals

More from Business